Biopharma's long-heralded return to R&D ROI may come up short this year, according to EvaluatePharma, and the next class of approved drugs features fewer blockbusters in waiting than in any of the previous four years.
To successfully launch a new drug in a crowded market, you need a way to differentiate your product. Lundbeck may have found just that, in the form of a study showing that its new antidepressant, Brintellix, helped patients think, concentrate and remember.
The vaccine, which is designed to work through early inhibition of amyloid beta depositions, is due to enter Phase I trials next year.
Lundbeck and its partners at Otsuka are embarking on a lengthy Phase III journey in search of solid evidence that their Alzheimer's drug Lu AE58054 in combination with donepezil can improve the swiftly eroding cognitive functions of Alzheimer's patients.
Regulators at the FDA stamped an approval on Brintellix, a new therapy to treat major depression from Lundbeck and Takeda, just hours before the government prepared to hunker down in a partial shutdown.
Danish drugmaker Lundbeck has been hiring more than 200 sales reps in the U.S. in anticipation of the FDA approval of the blockbuster antidepressant Brintellix. Well, now they have something to sell.
Supply-chain simplification and new procurement processes are also part of the plan.
The pharma company expects to save about a half billion Danish kroner annually in the move.
Steps taken by Danish drugmaker Lundbeck to keep U.S. states from using one of its drugs to execute prisoners are working, sort of. States are running out of unexpired supplies of Lundbeck's pentobarbital but are turning to alternatives, not halting executions.
Lundbeck is fired up and ready for its launch of the potential blockbuster antidepressant Brintellix. Though still awaiting regulatory approval, the Danish drugmaker is recruiting more than 200 sales reps to prepare for take-off, Bloomberg reports.